Company intelligence / Profile preview

Osmopharm

Bedano, Ticino, Switzerland

Ownership: Private
Employees: ~38
Development stage: Other

Overview

Osmopharm is a Swiss GMP-certified pharmaceutical contract manufacturer specializing in the development and commercial production of modified release oral solid dosage drugs, primarily as pellets, capsules, and tablets, serving over 100 clients worldwide and offering more than 150 formulations across a broad range of small molecule APIs. No proprietary clinical assets; work is focused on contract manufacturing and formulation rather than original drug development.[1][2][3][4][5]

Modalities: Small molecule
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Osmopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osmopharm.

Explore the full profile